We are an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders.
Joined August 2019
- Tweets845
- Following352
- Followers3.5K
- Likes51
AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer
bit.ly/4BKOvm4
$AIM #PancreaticCancer #Oncology #CancerResearch
Why wait for the next outbreak to prepare? AIM ImmunoTech CEO Tom Equels discusses broad-spectrum antiviral preparedness and Ampligen’s previously published Ebola research.
bit.ly/4je25aZ
Pancreatic cancer remains one of the most challenging cancers to treat, in part due to its highly immunosuppressive, or “cold,” tumor microenvironment.
At $AIM, we’re investigating how Ampligen may help reshape the tumor microenvironment and enhance anti-tumor immune responses.
AIM ImmunoTech has expanded European and U.K. patent protection for Ampligen in Long COVID and post-viral symptoms through 2041.
bit.ly/4ihm2wt
What is a TLR3 agonist?
TLR3 plays a role in activating the body’s innate immune response. Ampligen is a highly selective TLR3 agonist and has the potential to reshape the tumor microenvironment and support an anti-tumor immune response.
$AIM #Oncology #CancerResearch
Med World News looks at AIM ImmunoTech’s Phase 2 DURIPANC study and Ampligen’s potential role in addressing immune resistance in pancreatic cancer.
bit.ly/4g18WBs
AIM ImmunoTech’s Ampligen strategy takes aim at immune resistance in pancreatic cancer.
Read more in PharmaTech News: bit.ly/3Ro29cK
Want to keep up with the latest from $AIM?
From clinical progress to corporate news and other important developments, get AIM ImmunoTech updates delivered directly to your inbox.
Sign up for email alerts: bit.ly/3rp8t3N
#Oncology #CancerResearch
Check out the latest BioTuesdays article featuring $AIM and Ampligen, highlighting its potential across oncology, immune disorders and viral diseases, including ongoing research in pancreatic cancer.
Read more: bit.ly/4yFxLuM
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
bit.ly/4hNdNXO
$AIM #PancreaticCancer #Oncology #CancerResearch
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
bit.ly/4i1Oi65
$AIM #PancreaticCancer #Oncology #CancerResearch
This #BreastCancerAwarenessMonth, $AIM recognizes the patients, families, caregivers and advocates impacted by breast cancer.
We join the broader community in raising awareness and supporting continued progress in breast cancer research.
AIM ImmunoTech Spotlights Growing Attention Around Ampligen Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
bit.ly/4rHDxJD
$AIM #PancreaticCancer #Oncology #CancerResearch
$AIM CEO Thomas K. Equels discusses how Ampligen® could complement emerging pancreatic cancer therapies, including supportive survival observations and upcoming Phase 2 DURIPANC milestones.
Watch the latest CEO Corner: vimeo.com/1231443780/367fab9…
#Oncology #CancerResearch
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
bit.ly/4e5cr9s
$AIM #PancreaticCancer #Oncology #CancerResearch
Stay connected to what’s next at AIM ImmunoTech.
Sign up for email alerts to receive the latest company news, clinical updates, press releases and other important developments directly to your inbox.
Stay informed: bit.ly/3rp8t3N
$AIM #Oncology #CancerResearch
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
bit.ly/4xzTtPv
$AIM #PancreaticCancer #Oncology #CancerResearch
#DidYouSee?
$AIM reached a key milestone ahead of schedule in the Phase 2 DURIPANC trial, with the final patient receiving their last dose of Ampligen®.
Primary endpoint analysis is anticipated to begin in December 2026.
Read more: bit.ly/3TyX4iq
#Oncology
$AIM CEO Thomas K. Equels discusses Ampligen® and its continued advancement in pancreatic cancer, including the Phase 2 DURIPANC study and its potential to reshape the tumor microenvironment.
Watch the latest CEO Corner: vimeo.com/1225219727/91a420c…
#Oncology #CancerResearch
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
bit.ly/4hfLxxI
$AIM #PancreaticCancer #Oncology #CancerResearch
